Posts

Health Canada Grants Special Access to Restricted Drugs for Psychedelic TherapyShutterstock

Health Canada Grants Special Access to Restricted Drugs for Psychedelic Therapy

New amendment reverses a 2013 Health Canada policy that prevented "a letter of authorization for a new drug that is or that contains a restricted drug."

Psychedelic Business Spotlight: December 3

This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.

Psychedelic Business Spotlight: November 12

This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
3 Reasons Why Diversity, Equity and Inclusion Matter in the Psychedelic Industry

Why Diversity, Equity and Inclusion Are Vital to the Psychedelic Industry

Steven Huang, a consultant for leading psychedelic medicine company Numinus, explains why the industry should "harness the power of diversity."
Psychedelic Business Spotlight: August 6, 2021

Psychedelic Business Spotlight: August 6, 2021

Another clinic gets approval to conduct MDMA research, and new psychedelic research facilities open in Australia and the U.S., plus two game-changing psilocybin patents.
Psychedelic Business Spotlight, July 16

Psychedelic Business Spotlight: July 16, 2021

This week in psychedelic business news: A generous donation to advance MDMA research, psilocybin for end-of-life anxiety, and provisional patents filed for synthesizing ibogaine.